ArticleCancer management and research2026
A Retrospective Study of a Postoperative Inflammation-Based Score for Predicting Disease-Free Survival in Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiotherapy.
Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Growing research findings highlight the potential of inflammatory markers measured after surgery as prognostic indicators for survival outcomes in rectal carcinoma patients. However, their precise clinical significance remains inadequately explored within the specific population of locally advanced rectal carcinoma (LARC) patients receiving neoadjuvant chemoradiotherapy (NCRT), particularly regarding therapeutic response evaluation and long-term disease progression patterns. Methods: This investigation enrolled 260 participants diagnosed with LARC who underwent NCRT from 2014 to 2024. The study measured postoperative neutrophil-lymphocyte ratio (NLR) and monocyte-lymphocyte ratio (MLR) through ROC curve analysis to evaluate systemic inflammation. Participants were categorized into three cohorts based on inflammation-based postoperative biomarker score (IPBS): Score 0 (postoperative NLR <3.21 with MLR <0.345), Score 2 (NLR >3.21 and MLR >0.345), and Score 1 encompassing cases not meeting these thresholds. Survival outcomes were analyzed using Kaplan-Meier methodology stratified by inflammatory marker levels and IPBS classifications. Multivariate Cox regression models were employed to identify prognostic factors influencing OS and DFS. Results: Initial univariate assessments revealed significant correlations between disease-free survival and several factors including ypTNM staging, histopathological evidence of vascular/lymphatic/perineural invasion, postoperative neutrophil-lymphocyte ratio, and the IPBS system. Subsequent multivariate modeling identified elevated ypTNM classification (HR=2.115, 95% CI:1.114-4.019, p=0.022) and increased IPBS (HR=1.798, 95% CI:1.049-3.083, p=0.033) as independent prognostic indicators for reduced DFS. Notably, postoperative NLR values failed to demonstrate statistical significance in multivariate evaluation (HR=1.588, 95% CI:0.910-2.772, p=0.104). Conclusion: The composite inflammation-based postoperative biomarker score model demonstrated superior predictive accuracy for DFS outcomes in LARC patients undergoing NCRT compared to isolated biomarker analysis or select histopathological characteristics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.